Ocata Therapeutics, Inc. , a leader in the field of Regenerative Ophthalmologya , today announced that it has entered into a definitive agreement with Allele Biotechnology & Pharmaceuticals, Inc. of San Diego, CA to access Allele's proprietary technology for generating human induced pluripotent stem cells . "Ocata can now take advantage of induced and embryonic pluripotent stem cells to produce commercially viable human tissue for transplantation.
http://ift.tt/1NbOrLU
http://ift.tt/1NbOrLU
No comments:
Post a Comment